

Claim 1 (Previously Presented). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that has at least 94% amphotericin B and 4% or less of impurity products, and a pharmaceutically effective carrier; and

administering a therapeutically effective amount of a said composition to a subject in need thereof.

Claim 2 (Previously Presented). The method of claim 1, wherein the amphotericin B is present in an amount greater than about 96%.

Claim 3 (Previously Presented). The method of claim 1, wherein the amphotericin B is present in an amount greater than about 98%.

Claim 4 (Original). The method of claim 1, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 5 (Original). The method of claim 1, wherein the administering step is intravenous.

Claim 6 (Previously Presented). A pharmaceutical composition, comprising:

an active ingredient that has at least 94% amphotericin B and 4% or less of impurity products, and a pharmaceutically acceptable carrier.

Claim 7 (Previously Presented). The composition of claim 6, wherein the amphotericin B is present in an amount greater than about 96%.

Claim 8 (Previously Presented). The composition of claim 6, wherein the amphotericin B is present in an amount greater than about 98%.


Claims 9-16 (canceled).

Claim 17 (Previously Presented). The method of claim 1, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 18 (Previously Presented). The composition of claim 6, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 19 (Previously Presented). A pharmaceutical composition that comprises:

an active ingredient that is at least 96% w/w of a compound of the following formula:



and a pharmaceutically acceptable carrier.


Claim 20 (Previously Presented). The composition of claim 19, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 21 (Previously Presented). The composition of claim 19, comprising less than 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 22 (New). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that has at least 94% amphotericin B polyene compound and a pharmaceutically effective carrier; and
administering a therapeutically effective amount of a said composition to a subject in need thereof.

Claim 23 (New). The method of claim 23, wherein the active ingredient that is at least 96% w/w of a compound of the following formula:



and a pharmaceutically acceptable carrier.

Claim 24 (New). The method of claim 22, wherein said pharmaceutically acceptable carrier is a lipid carrier.